Researchers from several top academic medical institutions will present their findings related to HAI therapy through live presentations, oral abstracts, and posters at the symposium.
BOSTON, Jan. 16, 2024 /PRNewswire-PRWeb/ -- Intera Oncology, maker of the only FDA-approved implantable pump for Hepatic Artery Infusion (HAI) therapy, announces independent research on HAI therapy will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) January 18-20 in San Francisco, California, USA.
Researchers from several top academic medical institutions will present their findings related to HAI therapy through live presentations, oral abstracts, and posters at the symposium. HAI therapy is a powerful treatment for patients with colorectal cancer (CRC) that has spread to the liver and those with intrahepatic cholangiocarcinoma (iCCA). Through the use of an implantable pump, a continuous flow of medication is administered directly into the hepatic artery, which serves as the primary blood supply for tumors. Individuals receiving HAI therapy can maintain their normal daily activities outside the hospital, visiting their oncologist bi-weekly for pump refills.
On January 19, Kelly Lafaro, M.D. of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, will deliver a presentation titled "Hepatic Arterial Infusion for Liver Disease: Answering Common Questions for New Programs" at a session for Emerging Local Therapies for Liver-Limited Hepatobiliary Cancers. Dr. Lafaro will discuss lessons learned and offer advice on how other centers can implement their own HAI therapy programs.
Additionally, several researchers from different institutions will present their findings as either a rapid oral abstract or poster presentation during the symposium:
"Hepatic arterial infusion pump chemotherapy in patients with advanced intrahepatic cholangiocarcinoma confined to the liver: A multicenter phase II trial"
Bas Groot Koerkamp, MD, PhD, Department of Surgery, Erasmus MC Cancer Institute
Rapid Oral Abstract: 433
Presentation Date: This oral abstract will be presented on January 19 at 10:40 am PST during the Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract.
"Phase II study evaluating the efficacy of PDS0301 in combination with hepatic artery infusion pump (HAIP) and systemic therapy for patients with metastatic colorectal cancer or intrahepatic cholangiocarcinoma"
Jonathan Matthew Hernandez, MD, National Cancer Institute
Trials in Progress Poster Abstract: TPS586
Presentation Date: The poster will be presented on Friday, January 19, from 12:30 pm to 2:00 pm PST in Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract.
"A phase II trial of induction systemic mFOLFIRINOX followed by hepatic arterial infusion of floxuridine and dexamethasone given concurrently with systemic mFOLFIRI as a first-line therapy in patients with unresectable liver-dominant intrahepatic cholangiocarcinoma (HELIX-1)"
Ramish Patel, MD, School of Medicine, Department of Surgery, Division of Surgical Oncology, Knight Cancer Institute, Oregon Health & Science University
Poster Abstract: 511
Presentation Date: This poster will be presented on January 19, from 12:30 pm to 2:00 pm PST in the Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.
"Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma"
Naaz Nasar, MD, Memorial Sloan Kettering Cancer Center
Poster Abstract: 522
Presentation Date: This poster will be presented on January 19, from 12:30 pm to 2:00 pm PST in the Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract.
"Validation of a novel web-based application for hepatic arterial infusion floxuridine dosing"
Carleton Scott Ellis, PharmD, Department of Pharmacy, University of Kentucky HealthCare
Poster Abstract: 15
Presentation Date: This poster will be presented on January 20 from 6:30 am to 7:55 am PST in the Cancers of the Colon, Rectum and Anus Tract.
An increasing body of clinical evidence and modernized therapy protocols have driven wider adoption of HAI as more physicians and patients have learned about the benefits of the treatment. To assist with increased demand, Intera Oncology provides newly established HAI programs with training and educational information on a range of HAI-related topics, including setup and management of HAI programs, and has a dedicated Medical Affairs team to help answer questions about HAI therapy.
To learn more about evidence supporting the use of HAI therapy, visit Intera Oncology at Exhibitor Booth #4 at #GI24.
ABOUT HEPATIC ARTERY INFUSION (HAI) THERAPY
Hepatic Artery Infusion (HAI) is a powerful, liver-directed therapy option for colorectal cancer that has spread to the liver or bile duct cancer (intrahepatic cholangiocarcinoma). Traditional systemic chemotherapy is usually delivered through a vein, requiring the drug to travel through the body's bloodstream to reach the liver. Only a small portion of the chemotherapy ultimately reaches tumors in the liver. With HAI therapy, the drug is delivered directly to the liver through the hepatic artery using the Intera 3000 HAI Pump, which is implanted just below the skin in the abdomen. This precise, localized delivery provides up to 400 times higher drug concentration to the tumors compared to systemic chemotherapy, [1] and limits potential side effects elsewhere.
For patients with colorectal cancer that has spread to the liver, HAI therapy has been shown in clinical studies to reduce tumor size, improve disease control in the liver, and increase the likelihood that surgeons will be able to remove the tumors.[2,3] Studies have also demonstrated the potential of HAI therapy to prevent or delay recurrence after tumor removal and increase overall survival. [3,4,5,6]
For patients with iCCA, the median survival when treated with systemic chemotherapy alone is 13 to 17 months with almost no survivors at 3 years. Adding HAI to systemic chemotherapy has been associated with an increased three-year survival rate of 39.5%. [6,7]
ABOUT INTERA ONCOLOGY:
Intera Oncology® Inc. is a Boston-based medical device company founded in 2019 by two doctors with a singular vision for improving the survival of patients with colorectal cancer and intrahepatic cholangiocarcinoma by ensuring access to Hepatic Artery Infusion (HAI) therapy. Dedicated to helping patients live longer and better lives by changing the course of cancer with HAI therapy, Intera Oncology manufactures the only FDA-approved pump for HAI therapy – the Intera 3000 Hepatic Artery Infusion Pump. Today, the treatment is used in more than 50 cancer centers across the U.S., including nine of the U.S. News & World Report's top ten in the nation. Learn more at interaoncology.com and follow Intera on X, LinkedIn and Facebook.
References
[1] Ensminger WD, Gyves JW. Semin Oncol. 1983 Jun;10(2):176-82
[2] Pak L, et al. J Surg Oncol. 2018;117(4):634–643
[3] Kemeny N, et al. N Engl J Med. 1999;341(27):2039-2048
[4] Dhir M, et al. Ann Surg Oncol. 2017;24(1):150-158
[5] Groot Koerkamp B, et al. J Clin Oncol. 2017; 35(17): 1938–1944
[6] Holster J, et al. Ann Surg Oncol, 2022;29(9):5528–5538.
[7] Cercek A, et al. JAMA Oncol. 2022;6(1):60-67
Media Contact
Patricia Caballero, Intera Oncology, 1 973-348-5055, [email protected]
SOURCE Intera Oncology
Share this article